Brief: CytRx announces overall survival results from phase 2b clinical trial of Aldoxorubicin

LadRx

22/01/2015 14:00

Jan 22 (Reuters) - CytRx Corp  CYTR.O : 
 * Announces overall survival results from its global phase 2b clinical trial of 
   Aldoxorubicin in soft tissue sarcoma 
 * Aldoxorubicin demonstrates 2-fold increase in likelihood of surviving more 
   than 2 years versus doxorubicin and 27% reduction in risk of death 
 * Says adverse events were consistent with known doxorubicin toxicities 
 * Final results assessed as part of planned secondary endpoint analysis,were 
   not powered to demonstrate statistically significant overall survival 
 * Positive trend could be significantly improved, now that FDA has permitted 
   CytRx to dose aldoxorubicin in all trials until tumor progression 
 * Source text for Eikon  ID:nPn15LGq5  
 * Further company coverage  CYTR.O  
 
 ((Bengaluru Newsroom; +1 646 223 8780))